LONDON (ShareCast) - Essentially, the buy case for Daily Mail is sound, but the problem in the current climate is sentiment, says the Times.

Further evidence of softness in consumer demand seems more likely than not, and that is likely to create an even cheaper entry point for investors. The exact timing, however, is difficult; DMGT is a long-term buy at these levels, but the savvy investor should hang back and take advantage of what is likely to be further weakness in the share price.

Shell has eight weeks to conduct due diligence into its proposed deal to buy into Regal Petroleum's Ukraine assets, meaning there is no certainty the deal will proceed in its current form. But the interest of an oil major in an asset whose value was once all but written off gives long-suffering Regal investors reason to hold on at 164p says the Times.

The £220m of annualised sales brought with the acquisition of Reliant Pharmaceuticals will not do much for the vigour of GlaxoSmithKline's top line, but Reliant's key drug, Lovaza, gives GSK a foothold in the $20bn US cholesterol control market. With US regulatory approval for Cervarix due in January, GSK may remain volatile. But at £11.60, or 11 times 2008 year earnings, and yielding 5%, GSK is worth buying says the Times.

Accsys Technologies has developed a process that can turn soft wood into hard wood. Two major licensing deals have been signed in the past few weeks, and the deal with Diamond Wood China looks particularly juicy. This is no stock for the faint-hearted but new contracts are in the pipeline, and for higher-risk investors this looks well worth tucking away. Buy says the Independent.

It is encouraging to hear travel group Thomas Cook talking so confidently about its future, but there are too many unanswered questions to warrant recommending a buy on the stock at this stage. For investors in the stock, hang on. For everyone else, don't raid the holiday money just yet. Hold says the Independent.

In the short term, although Thomas Cook looks to be on track there are too many factors outside its control that could blow it off course. Soaring oil prices and the potential consumer slowdown are likely to keep the share price in check. Those sunny days could take some time yet to emerge. Sell says the Telegraph.

Paypoint supplies clever little machines that let customers pay everything from their TV licence to the congestion charge in cash. Growth prospects remain good both at home with pre-paid debit cards, and abroad with the company's imminent launch of a mobile billing service in Romania. On 18 times next year's earnings, with a yield of 2.8pc this is worth picking up. Buy says the Telegraph.

Paypoint shares stand on a prospective multiple of 19, which looks high enough until further evidence emerges that the company can operate successfully abroad and on the internet says the FT.

Two issues in the past have clouded the investment case for United Drug: one was the uncertain impact of the Boots UniChem merger: the other was the new price regime in Ireland. As regards the first, it has actually picked up market share in Ireland. On the second threat, again United Drug would appear reasonably placed to weather the storm. The shares look cheap at 13 times 2008 earnings of about 23 cents. Celesio, albeit a much bigger company, is trading at 16 times says the FT.

Fears that it will need additional financing to develop the bulk of the gold in these deposits and bring them to production have hit Oxus Gold shares. Although Oxus has a number of interests in Central Asia, the broker thinks that an industry-wide reluctance to invest in Uzbekistan means it is unlikely to be a takeover target. Sell says the Telegraph.

Outsource group Tribal's strategic review proved a disappointment. Tribal said it could make some selective acquisitions and will focus on better integrating its service across its disparate businesses. Tribal is a very illiquid stock and shares have nose-dived nearly 14% over the past week, so investors may prefer to hold until upward momentum is restored. Hold says the Independent.




Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.

• News Channel